In this study, we identified a novel ETS family fusion transcript, SLC45A3-ELK4, and found it to be expressed in both benign prostate tissue and prostate cancer.     ///    SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer..     ///    "Based on quantitative PCR analyses of DNA, unlike other ETS fusions described in prostate cancer, the expression of SLC45A3-ELK4 mRNA is not exclusive to cases harboring a chromosomal rearrangement. "    ///    "Altogether, our findings show that SLC45A3-ELK4 mRNA expression is heterogeneous, highly induced in a subset of prostate cancers, androgen regulated, and most commonly occurs through a mechanism other than chromosomal rearrangement (e.g., trans-splicing).. "    ///    SLC45A3-ELK4 transcript can be detected at high levels in urine samples from men at risk for prostate cancer.     ///    "Treatment of LNCaP cancer cells with a synthetic androgen (R1881) revealed that SLC45A3-ELK4, and not endogenous ELK4, mRNA expression is androgen regulated. "    ///    We found high levels of SLC45A3-ELK4 mRNA restricted to a subset of prostate cancer samples. 